Figure 4. Western blotting. A: Western blotting comparing complement C3 in CRVO + ranibizumab (lanes 1–5) versus CRVO + NaCl (lanes 6–12). B: Densitometric data corresponding to (A) confirmed downregulation of complement C3 (p = 0.048).